Sulfuric Acid

Sulfuric Acid

SCHEMBL3859535

O=S(=O)([O-])O.O=S(O)(O)=S.[Na+]

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CYP51cyp51Acyp51c

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.75
MEN1 O00255 1/20 0.75
ALDH1A1 P00352 1/20 0.75
KMT2A Q03164 1/20 0.75
CA5A P35218 2/20 0.39
CA5B Q9Y2D0 2/20 0.39
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
NT5E P21589 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiosulfuric Acid SCHEMBL10958542 0.92 TSHR (0.61) TSHRMEN1ALDH1A1KMT2ACA5A
Thiosulfuric Acid SCHEMBL6546202 0.92 TSHR (0.61) TSHRMEN1ALDH1A1KMT2ACA5A
Sulfuric Acid SCHEMBL1232606 0.92 TSHR (0.61) TSHRMEN1ALDH1A1KMT2ACA5A
Thiosulfuric Acid SCHEMBL3721921 0.92 TSHR (0.61) TSHRMEN1ALDH1A1KMT2ACA5A
Thiosulfuric Acid SCHEMBL3422846 0.92 TSHR (0.61) TSHRMEN1ALDH1A1KMT2ACA5A
Thiosulfuric Acid SCHEMBL2818447 0.88 TSHR (0.57) TSHRMEN1ALDH1A1KMT2ACA5A
Sulfuric Acid SCHEMBL28725361 0.88 TSHR (0.69) TSHRMEN1ALDH1A1KMT2ACA5A
Thiosulfuric Acid SCHEMBL28587397 0.88 TSHR (0.57) TSHRMEN1ALDH1A1KMT2ACA5A
Thiosulfuric Acid SCHEMBL8459656 0.88 TSHR (0.57) TSHRMEN1ALDH1A1KMT2ACA5A
Thiosulfuric Acid SCHEMBL7615104 0.88 TSHR (0.57) TSHRMEN1ALDH1A1KMT2ACA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119998400-A Polycarbonate compositions, methods for preparing the same, and articles comprising the polycarbonate compositions 高新特殊工程塑料全球技术有限公司 2025-05-13 CN disclosed
CN-119278237-A Anti-drip polycarbonate compositions 高新特殊工程塑料全球技术有限公司 2025-01-07 CN disclosed
CN-118984851-A PBT-alumina composite particles, methods, and molded parts 高新特殊工程塑料全球技术有限公司 2024-11-19 CN disclosed
CN-118632900-A Thermoplastic composition 高新特殊工程塑料全球技术有限公司 2024-09-10 CN disclosed
CN-116041597-B Polybutadiene latex and ABS resin and preparation method thereof 金发科技股份有限公司 2024-08-13 CN disclosed
CN-116848192-A Thermoplastic composition 高新特殊工程塑料全球技术有限公司 2023-10-03 CN disclosed
CN-116041597-A Polybutadiene latex and ABS resin and preparation method thereof 金发科技股份有限公司 2023-05-02 CN disclosed
US-20150315188-A1 COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION MEDIVATION TECHNOLOGIES, INC. 2015-11-05 US disclosed
EP-2887805-A1 COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION Medivation Technologies, Inc. (US) 2015-07-01 EP disclosed
WO-2014031170-A1 PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2014-02-27 WO disclosed
WO-2014031167-A1 COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION MEDIVATION TECHNOLOGIES, INC. (US) 2014-02-27 WO disclosed
WO-2014031165-A1 COMPOUNDS AND METHODS OF TREATING DIABETES MEDIVATION TECHNOLOGIES, INC. (US) 2014-02-27 WO disclosed
EP-1608622-A4 BIARYL SUBSTITUTED 6-MEMBERED HETEROCYLES AS SODIUM CHANNEL BLOCKERS MERCK & CO INC (US) 2009-04-01 EP disclosed
US-20060293339-A1 Biaryl substituted 6-membered heterocycles as sodium channel blockers MERCK SHARP & DOHME CORP. 2006-12-28 US disclosed
EP-1608622-A2 BIARYL SUBSTITUTED 6-MEMBERED HETEROCYLES AS SODIUM CHANNEL BLOCKERS Merck & Co., Inc. (US) 2005-12-28 EP disclosed
WO-2004084824-A2 BIARYL SUBSTITUTED 6-MEMBERED HETEROCYLES AS SODIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315188-A1 COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION ADRB2, ADRA2B, ADRB1 TSHR 282/4885MEN1 1907/4885ALDH1A1 718/4885
US-20060293339-A1 Biaryl substituted 6-membered heterocycles as sodium channel blockers TRPV1, SCN2A, SCN2B TSHR 1527/4885MEN1 2432/4885ALDH1A1 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.